Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results

Go back to Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results
(NASDAQ: VIRI) Delayed: 0.16 --0 (-0%)
Previous Close $0.16    52 Week High
Open $0.16    52 Week Low
Day High $0.16    P/E N/A 
Day Low $0.16    EPS
Volume 65,015